Medical Patent News

RSS

Court of Appeals rules in favor of Mylan in Oxybutynin patent case

Mylan Laboratories Inc. has announced that the U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Mylan's Oxybutynin products do not infringe a patent for DITROPAN XL and that the patent was invalid.

11 Sep 2006

Pfizer wins Norvasc patent challenge

Pfizer has said that a federal court in the Middle District of North Carolina has upheld the company's U.S. patent covering amlodipine besylate, the active ingredient in Norvasc, the world's most-prescribed branded medicine for treating hypertension.

4 Sep 2006

Purdue Pharma announces agreement to end OxyContin patent lawsuit with Teva Pharmaceuticals

Purdue Pharma L.P. of Stamford, Connecticut and Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin (oxycodone HCl controlled-release) Tablets.

30 Aug 2006

Ranbaxy wins two additional Atorvastatin patents in Norway

Ranbaxy Laboratories Limited has announced that a Norwegian court handed down a favorable decision for Ranbaxy in its case against Pfizer, involving two patents on atorvastatin in Norway.

30 Aug 2006

Morphotek granted two European technology patents

Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetically Altered Antigens."

30 Aug 2006

Ryogen licenses gene patent to OriGene Technologies

Ryogen and OriGene Technologies have announced today that they have entered into a nonexclusive license agreement whereby OriGene has licensed from Ryogen the patent directed to the clinically important Aminopeptidase P gene.

15 Aug 2006

ZymoGenetics files lawsuit against Bristol-Myers Squibb

ZymoGenetic has announced that it has filed a lawsuit against Bristol-Myers Squibb for infringement of its patents related to fusion protein technology.

15 Aug 2006

Boston Life Sciences announces issuance of U.S. patent for methods to diagnose ADHD

Boston Life Sciences has announced that the U.S. Patent and Trademark Office has issued a patent to the President and Fellows of Harvard College, the General Hospital Corporation and Organix that covers methods of diagnosing and monitoring attention deficit hyperactivity disorder (ADHD) by assessing the level of dopamine transporter (DAT) in at least one region of a patient's central nervous system.

14 Aug 2006

Palomar sues for patent infringement

Palomar Medical Technologies has announced that it filed a lawsuit in the U.S. District Court for the District of Massachusetts against Candela Corporation for patent infringement.

14 Aug 2006

New U.S. patent issued to Archus Orthopedics

Archus Orthopedics has announced that it has been awarded its seventh United States Patent.

14 Aug 2006

Recently patented technology promotes early warning of pandemics

Rapid analysis and response in the very early stages of a pandemic or bioterrorism event can sharply limit its deadly impact.

10 Aug 2006

Oragenics issued new patent for novel antibiotic peptide

Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140.

8 Aug 2006

Ranbaxy invalidates Pfizer's '995 Lipitor U.S. patent

Ranbaxy announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer.

2 Aug 2006

SRU Biosystems OK'd to conduct business

SRU Biosystems announces the United States District Court for the District of Delaware has resolved in SRU's favor a dispute over the content and scope of a permanent injunction order sought by Corning.

2 Aug 2006

Pfizer's atorvastatin (Lipitor) patent safe

Pfizer Inc said today that a panel of the Court of Appeals for the Federal Circuit has upheld the exclusivity of the main patent covering atorvastatin, the active ingredient in Lipitor, maintaining patent protection for Lipitor in the U.S. until March 2010.

2 Aug 2006